Northeast Pharmaceutical Group To Give Up Stake In ShenYang TCM Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
The Shenyang Property Rights Transaction Center's information shows that Northeast Pharmaceutical Group plans to transfer its 20 percent stake in ShenYang TCM Pharmaceutical at a price of RMB 35 million ($5.1 million). ShenYang TCM Pharmaceutical, a Sino-British joint venture, is one of China's key TCM pharmaceutical companies. It mainly engages in Chinese patent medicine R&D, processing and manufacturing; TCM extraction; herbal medicine processing; as well as medicinal raw material purchasing. The firm's major product Shenyang Hongyao has become a renowned brand in the nation's TCM industry. A manager of the transaction reveals that Northeast Pharmaceutical Group's move stems from investment restructuring, which will focus the development of its core chemical medicine business. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.